Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 14,907 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cerebral Disorder Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals

NCT06117020
View directory record Official record
Conditions
Muscle Spasticity, Hypertonia, Muscle, Cerebral Palsy, Multiple Sclerosis, Stroke, Hereditary Spastic Paraplegia, Dystonia, Spinal Cord Injuries
Interventions
MTR-601
Drug
Lead sponsor
Motric Bio
Industry
Eligibility
18 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 1 Interventional

Vagus Nerve Stimulation to Treat Moderate Traumatic Brain Injury

NCT02974959
View directory record Official record
Conditions
Traumatic Brain Injury, Acute Brain Injuries
Interventions
gammaCore active device, gammaCore sham device
Device
Lead sponsor
CentraCare
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 2 Interventional

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

NCT00075959
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
NXY-059
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
64
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 1 Interventional

Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

NCT01259479
View directory record Official record
Conditions
Solid Tumors, Brain Tumors, Brain Metastases
Interventions
Satraplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 3 Interventional

A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome

NCT00017927
View directory record Official record
Conditions
McCune Albright Syndrome, Polyostotic Fibrous Dysplasia
Interventions
Pegvisomant
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 2 Interventional

Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

NCT00892931
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Azixa
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2011 · Synced Jun 25, 2026, 6:41 PM EDT
Terminated Not applicable Interventional Results available

Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma

NCT00631137
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Musculoskeletal Complications
Interventions
testosterone gel applied to skin, whey powder protein
Drug · Dietary Supplement
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Jun 25, 2026, 6:41 PM EDT
Not listed Not applicable Interventional

Unwinding Anxiety for Migraine: Pilot

NCT06150612
View directory record Official record
Conditions
Migraine, Anxiousness
Interventions
Unwinding Anxiety
Behavioral
Lead sponsor
Yeshiva University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Histamine, CGRP and VIP as Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers

NCT00208065
View directory record Official record
Conditions
Migraine, Sinusitis
Interventions
almotriptan or pseudoephedrine
Drug
Lead sponsor
Clinvest
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 5, 2009 · Synced Jun 25, 2026, 6:41 PM EDT
Recruiting Phase 2 Interventional

Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy

NCT07434492
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Smart Ankle-Foot Orthosis, 5-Azacitidine, Placebo
Device · Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
8 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Enrolling by invitation Phase 2 Interventional

Sirolimus for Leigh Syndrome

NCT06843811
View directory record Official record
Conditions
Leigh Syndrome
Interventions
Sirolimus
Drug
Lead sponsor
Matthew Demczko
Other
Eligibility
6 Months to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Noninvasive Modulation of Motivational Brain Regions in Healthy Volunteers

NCT04972786
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Jun 25, 2026, 6:41 PM EDT
Recruiting Phase 2 Interventional

Personalized Brain Stimulation to Treat Chronic Concussive Symptoms

NCT06073886
View directory record Official record
Conditions
Post-Concussion Syndrome, Concussion, Brain, Mild Traumatic Brain Injury, Head Injury, Headache, Dizziness, Cognitive Symptom, Dysautonomia, Anxiety, Irritability; Syndrome, Depression, Post-traumatic Stress Disorder
Interventions
Active cTBS, Inactive/Sham cTBS, Imaginal exposure
Device · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Terminated No phase listed Observational

LOTUS: Global Acute Stroke Study Utilizing Penumbra System

NCT04157270
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
Penumbra System
Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Englewood, Colorado • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Jun 25, 2026, 6:41 PM EDT
Not listed Phase 3 Interventional

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

NCT02615873
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Accordion Pill™ Carbidopa/Levodopa
Drug
Lead sponsor
Intec Pharma Ltd.
Industry
Eligibility
30 Years to 100 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

NCT00671970
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Bevacizumab and Erlotinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2013 · Synced Jun 25, 2026, 6:41 PM EDT
Recruiting No phase listed Observational

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

NCT06539169
View directory record Official record
Conditions
Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions
Not listed
Lead sponsor
xCures
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional

Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury

NCT03307070
View directory record Official record
Conditions
Major Depressive Disorder, Traumatic Brain Injury
Interventions
Cognitive Behavioral Therapy for individuals with TBI, Waitlist Control
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Jun 25, 2026, 6:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma

NCT01044966
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioma, Astrocytoma, Brain Tumor
Interventions
ITV DepoCyt + Temozolomide
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Jun 25, 2026, 6:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Studies of Brain and Body Interaction

NCT03672266
View directory record Official record
Conditions
Autistic Disorders Spectrum, Adhd, Asperger Syndrome, Alzheimer Disease, Parkinson, Tremor Essential, Dementia, Alzheimer Type, Lewy Body Dementia With Behavioral Disturbance (Disorder), Dementia With Lewy Bodies, Dementia Frontal
Interventions
Not listed
Lead sponsor
Rutgers University
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 25, 2026, 6:41 PM EDT
Completed No phase listed Observational

Addressing Real-world Anticoagulant Management Issues in Stroke

NCT02478177
View directory record Official record
Conditions
Stroke, Cerebrovascular Stroke, Intracerebral Hemorrhage
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional

Precision Clinical and Genetic Tools for Brain Health in Hemorrhagic Stroke

NCT05643001
View directory record Official record
Conditions
Hemorrhagic Stroke
Interventions
In-patient and out-patient electronic health record alert
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Results available

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)

NCT01074944
View directory record Official record
Conditions
Gaucher Disease
Interventions
Eliglustat tartrate
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
10
States / cities
San Diego, California • New Haven, Connecticut • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Jun 25, 2026, 6:41 PM EDT
Completed Not applicable Interventional

Self-management EdUcation and SuPport to Promote PsychOsocial Health Among StRoke Survivors and Informal Caregivers in a VirTual Stroke Community (SUPPORT)

NCT05487144
View directory record Official record
Conditions
Stroke
Interventions
Learning in a Virtual Environment (LIVE)
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Jun 25, 2026, 6:41 PM EDT